Arrhythmias and Conduction DisturbancesAntiarrhythmic Drug Use in Patients <65 Years With Atrial Fibrillation and Without Structural Heart Disease
Section snippets
Methods
The study cohort was obtained from the Thomas Reuters MarketScan Commercial Claims and Encounters Database. This database consists of inpatient, outpatient, and prescription claims data from US employers who provide health plans for their employees and employees' spouses and dependents. The MarketScan database has primarily been used for health care utilization and outcome studies of a variety of diseases, including AF.1, 2, 3 For purposes of this analysis, we obtained data on all patients with
Results
After excluding a small number of patients who initially received dofetilide (n = 46; Figure 1), a total of 8,562 patients <65 years with AF, but without CAD or heart failure, were included in the final study cohort. In this final cohort, use of a class Ic drug was found in 35% of patients, followed by amiodarone (34%), sotalol (24%), and dronedarone (7%). In those receiving a class Ic drug, 51.5% received flecainide and 48.5% received propafenone. Of the 8,562 patients in the overall study
Discussion
When the decision is made to use an AAD for the management of paroxysmal or persistent AF, selection of the most appropriate AAD should be based on patient-specific characteristics to minimize potential risk from the AAD. Patients without CAD and heart failure have a greater number of guideline-recommended AAD options,8, 9, 10 yet not all these options are optimal, given an individual patient's co-morbidities and each drug's unique properties. In this study, we provide the first description of
Acknowledgment
The authors would like to thank Louise Zimmer, MA, MPH, and Rosalia Blanco, MBA, for co-ordinating statistical resources. The authors would also like to thank Erin Hanley, MS, for editorial contributions to this report. Zimmer, Blanco, and Hanley did not receive compensation for their contributions, apart from the employment at the institution where this study was conducted.
References (21)
- et al.
Increasing prevalence of atrial fibrillation and flutter in the United States
Am J Cardiol
(2009) - et al.
Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutter
Am J Cardiol
(2012) - et al.
Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation
Am Heart J
(2013) - et al.
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society
J Am Coll Cardiol
(2014) - et al.
Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000
Am J Cardiol
(2003) - et al.
Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation
Am Heart J
(2007) - et al.
Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II)
Heart Rhythm
(2010) - et al.
Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry)
Am J Cardiol
(2010) - et al.
Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study)
Int J Cardiol
(2013) - et al.
One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis
Clin Ther
(2011)
Cited by (24)
Simultaneous determination of amiodarone, dronedarone, and their principal metabolites in SD rat plasma by UPLC-MS/MS and its application in pharmacokinetics
2021, Arabian Journal of ChemistryCitation Excerpt :These side effects are manifested in the adverse reactions of the heart, eyes, lungs, liver, dermatology, hematology, psychiatry, thyroid and neuromuscular, and epididymitis and syndrome of inappropriate secretion of antidiuretic hormone can even be caused by chronic amiodarone treatment (Biancatelli et al., 2019). Therefore, as the metabolism is slow and unpredictable, extracardiac toxicity is high and numerous drug interactions, almost one-third of patients cannot maintain long-term treatment for the severe adverse reactions (Allen LaPointe et al., 2015; Dan et al., 2018). Dronedarone (Fig. 1C), specifically developed for treating atrial fibrillation (AF), is a non-iodinated benzofuran, which was designed to retain the efficacy of amiodarone, with an improved safety profile.
Use of Flecainide for the Treatment of Atrial Fibrillation
2020, American Journal of CardiologyCitation Excerpt :In the TREAT-AF study, which employed propensity score matching, not only were hospitalization rates for AF or atrial flutter found to be lower with Class IC drugs, but also for cardiovascular disease, heart failure, and ischemic stroke.79 Another analysis using claims data80 found higher AF hospitalization rates with dronedarone and lower AF hospitalization rates with amiodarone, but no difference between sotalol and Class IC AADs. Thus, with the exception of amiodarone, the long-term efficacy of flecainide is comparable with other approved AADs.
The role of amiodarone in contemporary management of complex cardiac arrhythmias
2020, Pharmacological ResearchCitation Excerpt :Since randomized controlled trials in late 1980s and early 1990s showed that class I drugs were associated with increased mortality in patients with significant structural heart disease, largely due to life-threatening ventricular arrhythmias, attention has been redirected to the development of class III agents and amiodarone [4,6]. Amiodarone has long been used as a "drug of the last resort" but, currently, amiodarone is the most powerful and most commonly prescribed antiarrhythmic drug (AAD) for a „broad spectrum “of atrial and ventricular arrhythmias, accounting for approximately 30 % of the world AAD market [7]. However, due to its slow and unpredictable metabolism, high extracardiac toxicity and numerous drug-drug interactions, its use in clinical practice is a „two edged sword “and almost one-third of the patients are unable to sustain the long-term treatment due to serious adverse effects [6,7].
Flecainide: Electrophysiological properties, clinical indications, and practical aspects
2019, Pharmacological ResearchCitation Excerpt :Regardless of the guidelines recommendations, class IC drugs appear to be under used in everyday clinical practice, possibly due to an over perception of the severity of the side effects. A retrospective study on the American database “Thomas Reuters MarketsScan Commercial Claims and Encounters” documented an overall excessive use of amiodarone compared to IC drugs, while these latter were preferred in females, in patients with a history of atrial flutter, in patients with a known history of AF and in patients already treated with verapamil or diltiazem [29]. On the other hand, these drugs were avoided or scarcely used in older hospitalised patients, in patients with diabetes and in patients under anticoagulant treatment.
Practical Management Guide for Clinicians Who Treat Patients with Amiodarone
2016, American Journal of MedicineRate Control Versus Rhythm Control in the ORBIT-AF Registry the Beat Goes on
2016, JACC: Clinical Electrophysiology
See page 321 for disclosure information.